Press Releases Revance Therapeutics, Inc.

Equities

RVNC

US7613301099

Market Closed - Nasdaq Other stock markets 04:00:02 2024-05-16 pm EDT			5-day change	1st Jan Change
3.14 ^USD	-5.14%		-26.81%	-64.28%

May. 10	Needham Adjusts Price Target on Revance Therapeutics to $12 From $18, Maintains Buy Rating	MT
May. 10	Piper Sandler Cuts Price Target on Revance Therapeutics to $11 From $20, Maintains Overweight Rating	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY for the Treatment of Cervical Dystonia	May. 10	AQ
Revance Reports First Quarter 2024 Financial Results, Provides Corporate Update	May. 09	BU
Revance Expands into the U.S. Therapeutics Market with the Launch of DAXXIFY® for the Treatment of Cervical Dystonia	May. 09	BU
Revance to Release First Quarter 2024 Financial Results on Thursday, May 9, 2024	May. 02	BU
Revance to Present New DAXXIFY Data at the American Academy of Neurology 2024 Annual Meeting	Apr. 15	AQ
Northern District Of California Grants Motion To Dismiss Putative Class Action Against Biotech Company And Executives	Apr. 15	AQ
Revance to Present New DAXXIFY® Data at the American Academy of Neurology 2024 Annual Meeting	Apr. 12	BU
Revance Reports Inducement Grants under Nasdaq Listing Rule 5635(4)	Mar. 28	AQ
Revance Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	Mar. 27	BU
Court Finds Access To Botox Trade Secrets And Similarity Of Competitor Product Supported Inference Of Trade Secrets Misappropriation	Mar. 07	AQ
Revance Announces Pricing of $100.0 Million Public Offering of Common Stock	Mar. 04	BU
Revance Announces Proposed Public Offering of Common Stock	Mar. 04	BU
Revance Reports Fourth Quarter and Full Year 2023 Financial Results, Provides Corporate Update	Feb. 28	BU
Revance to Release Fourth Quarter and Full Year 2023 Financial Results on Wednesday February 28, 2024	Feb. 21	BU
Revance to Participate in Upcoming Investor Conferences	Feb. 21	BU
Revance Receives Permanent J-Code for DAXXIFY® and Announces Publication of DAXXIFY Pivotal Study (ASPEN-1) Results in Neurology®	Feb. 02	BU
Revance to Participate in the Guggenheim 6th Annual Biotechnology Conference	Feb. 01	BU
Revance Provides Corporate Update, Preliminary Fourth Quarter and Full Year 2023 Financial Results, and Financial Outlook	Jan. 08	BU
Revance Reports Third Quarter 2023 Financial Results, Provides Corporate Update	Nov. 08	BU
Revance Appoints Erica Jordan as Chief Commercial Officer, Aesthetics	Nov. 08	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Revance Therapeutics, Inc.

Equities

RVNC

US7613301099

Press Releases

Filters